INCY

MONTREAL, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. ("Knight") (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today it has received expedited regulatory approval under ANVISA's rare disease pathway for NIKTIMVO® (axatilimab), for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients 6 years and older weighing at least 40 kg.1

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Incyte (INCY) and Techne (TECH). But which of these two stocks is more attractive to value investors?

Mirum Pharmaceuticals wins FDA approval for Atebrioz in FOP, backed by PROGRESS data showing a reduction in new HO lesion volume.

NORTHRIDGE, Calif., Sept. 28, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced that Sheila Denton has been named General Counsel & Corporate Secretary.

The First Trust Large Cap Growth AlphaDEX ETF (FTC) was launched on 05/08/2007, and is a smart beta exchange traded fund designed to offer broad exposure to the Style Box - Large Cap Growth category of the market.

Incyte Corporation (INCY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Incyte's strong product demand and pipeline progress fuel its 23% YTD rally, but valuation and near-term earnings pressure temper the outlook.

Incyte Corporation (INCY) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

Launched on May 8, 2007, the First Trust Large Cap Growth AlphaDEX ETF (FTC) is a passively managed exchange traded fund designed to provide a broad exposure to the Large Cap Growth segment of the US equity market.